SCHEMBL12021191

SCHEMBL12021191

COC(=O)c1cc(I)c(C)cc1N

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CFTR P13569 6/20 0.62
KDM4E B2RXH2 7/20 0.56
ALDH1A1 P00352 6/20 0.50
GAA P10253 5/20 0.50
HSD17B10 Q99714 3/20 0.50
HPGD P15428 3/20 0.50
MAPT P10636 3/20 0.50
GLA P06280 2/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50
ATM Q13315 1/20 0.50
ABL1 P00519 1/20 0.49
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
NQO2 P16083 1/20 0.43
POLB P06746 1/20 0.40
CISD2 Q8N5K1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3970865 0.86 CFTR (0.54) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL28922445 0.85 CFTR (0.66) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL681252 0.85 KDM4E (0.63) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL25455691 0.83 CFTR (0.46) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL1920431 0.83 CFTR (0.46) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL30280800 0.83 CFTR (0.46) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL857614 0.81 KDM4E (0.74) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL16155019 0.81 CFTR (0.65) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL24918216 0.81 CFTR (0.60) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL857214 0.81 CFTR (0.60) CFTRKDM4EALDH1A1GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092065-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC (US) 2025-03-20 US disclosed
WO-2023133217-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC. (US) 2023-07-13 WO disclosed
WO-2023133217-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC. (US) 2023-07-13 WO disclosed
US-20130296332-A1 1H-QUINAZOLINE-2,4-DIONES NOVARTIS AG (CH) 2013-11-07 US disclosed
US-8513268-B2 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy NOVARTIS AG (CH) 2013-08-20 US disclosed
US-20110294818-A1 1H-QUINAZOLINE-2,4-DIONES NOVARTIS AG 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092065-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SNRPA, SNRPB2, HNRNPAB CFTR 3334/4885KDM4E 1965/4885ALDH1A1 2046/4885
US-20110294818-A1 1H-QUINAZOLINE-2,4-DIONES CYP1A2, QDPR, CYP3A7 CFTR 1584/4885KDM4E 1242/4885ALDH1A1 115/4885
US-20130296332-A1 1H-QUINAZOLINE-2,4-DIONES CYP1A2, QDPR, CYP3A7 CFTR 1584/4885KDM4E 1242/4885ALDH1A1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.